Abstract
Glycosylation is one of the major post-translational modifications, required for proper folding and functions of glycoproteins. N-glycosylation in ER is mediated by oligosaccharyltransferase (OST), an enzyme complex transferring preassembled oligosaccharide to asparagine residues of nascent polypeptide chain. Our study here indicates that regulator of calcineurin 1 (RCAN1) can enhance N-glycosylation in ER, therefore elevates the activities of β- and γ-secretase and markedly increases Aβ production. We found that RCAN1 stabilizes OST by interacting with OST component ribophorinI (RPN I). RCAN1 enhanced glycosylation of membrane proteins and glycosylation sequon GNSTVT, but has no effect on transferrin whose glycosylation was only affected by OST catalytic subunit STT3A, suggesting the effect of RCAN1 is associated with RPN I in facilitating substrate delivery. Our previous studies have shown that RCAN1 was increased in AD brains and RCAN1 overexpression induced neuronal apoptosis. Here our study showed that RCAN1 further contributes to AD pathogenesis by increasing N-glycosylation and Aβ production.
Keywords: Aβ, Alzheimer’s disease, β-secretase, γ-secretase, N-glycosylation, oligosaccharyltransferase, RCAN1.
Current Alzheimer Research
Title:RCAN1 Increases Aβ Generation by Promoting N-glycosylation via Oligosaccharyltransferase
Volume: 11 Issue: 4
Author(s): Tan Wang, Heng Liu, Yun Wang, Changqing Liu and Xiulian Sun
Affiliation:
Keywords: Aβ, Alzheimer’s disease, β-secretase, γ-secretase, N-glycosylation, oligosaccharyltransferase, RCAN1.
Abstract: Glycosylation is one of the major post-translational modifications, required for proper folding and functions of glycoproteins. N-glycosylation in ER is mediated by oligosaccharyltransferase (OST), an enzyme complex transferring preassembled oligosaccharide to asparagine residues of nascent polypeptide chain. Our study here indicates that regulator of calcineurin 1 (RCAN1) can enhance N-glycosylation in ER, therefore elevates the activities of β- and γ-secretase and markedly increases Aβ production. We found that RCAN1 stabilizes OST by interacting with OST component ribophorinI (RPN I). RCAN1 enhanced glycosylation of membrane proteins and glycosylation sequon GNSTVT, but has no effect on transferrin whose glycosylation was only affected by OST catalytic subunit STT3A, suggesting the effect of RCAN1 is associated with RPN I in facilitating substrate delivery. Our previous studies have shown that RCAN1 was increased in AD brains and RCAN1 overexpression induced neuronal apoptosis. Here our study showed that RCAN1 further contributes to AD pathogenesis by increasing N-glycosylation and Aβ production.
Export Options
About this article
Cite this article as:
Wang Tan, Liu Heng, Wang Yun, Liu Changqing and Sun Xiulian, RCAN1 Increases Aβ Generation by Promoting N-glycosylation via Oligosaccharyltransferase, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140331225855
DOI https://dx.doi.org/10.2174/1567205011666140331225855 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Strong Association of Serum GSK-3β/BDNF Ratio with Mild Cognitive Impairment in Elderly Type 2 Diabetic Patients
Current Alzheimer Research The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Pharmacogenomics in Aspirin Intolerance
Current Drug Metabolism Antioxidant Pathways in Alzheimers Disease: Possibilities of Intervention
Current Pharmaceutical Design Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic Evaluation of Callistemon viminalis Derived Natural Compounds as Targeted Inhibitors Against δ -Opioid Receptor and Farnesyl Transferase
Letters in Drug Design & Discovery Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Individual Triptan Selection in Migraine Attack Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Theoretical Study of Monoamine Oxidase B Inhibitors as Drug Candidates for Treatment of Parkinson’s Disease
Central Nervous System Agents in Medicinal Chemistry Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study
Current HIV Research